Results of Operations and Financial Condition. On August 13, 2026, the Company issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On August 13, 2026, the Company issued a press release entitled “MapLight Therapeutics Announces $150 Million Private Placement Financing” which includes the following selected preliminary financial information: MapLight’s c…

Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement as set forth under

Entry Into A Material Definitive Agreement. On August 13, 2026, MapLight Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 9,197,887 shares (the “ Shares ”) of the Company’s voting common stock, par value $0.0001 (“ Common Stock ”) per s…

Chief Financial Officer — Vishwas Setia: Mr. Setia was separated as CFO following a review of a human resources violation.

Results of Operations and Financial Condition. On May 14, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Excha…

Director — Robert Malenka, Jim Trenkle: Dr. Malenka and Dr. Trenkle decided not to stand for reelection, with successors already nominated.

Results of Operations and Financial Condition. On March 26, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of…

Results of Operations and Financial Condition. On January 9, 2026, MapLight Therapeutics, Inc. (the "Company") released the Presentation (as defined below), which includes the following selected preliminary financial information for the fiscal year ended December 31, 2025: As of December 31, 2025, the Company's cash and cash equivalents were approximately $450 million. The cash and cash equivalents information above and in the Presentation is preliminary, has not been audited and is subject t…

Results of Operations and Financial Condition. On December 4, 2025, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securiti…

Other Events. On October 26, 2025, the Company entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), in connection with the IPO, for the issuance and sale by the Company of 14,750,000 shares of Common Stock, at an initial public offering price of $17.00 per share, le…

Unregistered Sales of Equity Securities. The disclosure set forth below under